Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

LETYBO

(Letybo)

Small molecule

0

Indications

2

Total Trials

0

Active Trials

0

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

Clinical

Trials by Indication[1]

Prospective2 trials

Prospective, Non-interventional Study Assessing Periorbital Rejuvenation Procedure

Completed·YYuvell··NCT07398755·29 enrolled

A Prospective, Non-Interventional, Single-Centre Study Assessing the Efficacy of a Holistic Upper Face Treatment With Botulinum Neurotoxin A

Completed·YYuvell··NCT07374965·20 enrolled

Regulatory

FDA Approval Timeline[3]

Feb 29, 2024

LETYBO

BLA BLA761225

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Letybo. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Letybo compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
OpenFDA — FDA approval records (BLA BLA761225). U.S. Food & Drug Administration.
[4]
SEC EDGAR — Hugel company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: HHugel

Related News